Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics

Efficacious, safe, and stable inhibition of corneal neovascularization by AAV-vectored anti-VEGF therapeutics

Corneal neovascularization (CoNV) leads to visual impairment, affecting over 1.4 million people in the United States per year. It is caused by a variety of pathologies, such as inflammation, hypoxia, and limbal barrier dysfunction. Injection of the anti-vascular endothelial growth factor (VEGF) drug...

Full description

Bibliographic Details
Main Authors: Wenqi Su, Shuo Sun, Bo Tian, Phillip W.L. Tai, Yongwen Luo, Jihye Ko, Wei Zhan, Xiao Ke, Qiang Zheng, Xiaorong Li, Hua Yan, Guangping Gao, Haijiang Lin
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
corneal neovascularization
recombinant adeno-associated virus
anti-VEGF
gene therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050121001091

Internet

http://www.sciencedirect.com/science/article/pii/S2329050121001091

Similar Items